News Releases Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Go Month Year Su Mo Tu We Th Fr Sa 25 26 27 28 29 30 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 1 2 3 4 5 Cancel Go Investor Alerts Year All Years 2023 2022 2021 2020 2019 2018 2017 Keywords Go Advanced Search Search Search Headlines Only From To Asset Types Photos Video Audio Documents Events Standard Feb 23, 2023 Immunic, Inc. Reports Year End 2022 Financial Results and Provides Corporate Update Feb 22, 2023 Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023 Feb 16, 2023 Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2022, and Provide Corporate Update Feb 9, 2023 Immunic to Host Virtual Celiac Disease R&D Day to Highlight Current Pathways for Drug Development and Unmet Medical Need Jan 25, 2023 Immunic to Participate in Scientific and Investor Conferences in February Nov 17, 2022 Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug's Neuroprotective Potential Nov 10, 2022 Immunic to Participate in Investor and Scientific Conferences in November and December Nov 3, 2022 Immunic, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update Oct 27, 2022 Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update Oct 20, 2022 Immunic Reports Pre-Planned Phase 1b Interim Analysis of IMU-935 in Psoriasis Patients Confounded by High Placebo Rate Show 5102550100 per page«123456789…16»
